Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells in hypoxia-induced pulmonary hypertension by Schuoler, Claudio et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle
cells in hypoxia-induced pulmonary hypertension
Schuoler, Claudio <javascript:contributorCitation( ’Schuoler, Claudio’ );>; Haider, Thomas J
<javascript:contributorCitation( ’Haider, Thomas J’ );>; Leuenberger, Caroline
<javascript:contributorCitation( ’Leuenberger, Caroline’ );>; Vogel, Johannes
<javascript:contributorCitation( ’Vogel, Johannes’ );>; Ostergaard, Louise
<javascript:contributorCitation( ’Ostergaard, Louise’ );>; Kwapiszewska, Grazyna
<javascript:contributorCitation( ’Kwapiszewska, Grazyna’ );>; Kohler, Malcolm
<javascript:contributorCitation( ’Kohler, Malcolm’ );>; Gassmann, Max
<javascript:contributorCitation( ’Gassmann, Max’ );>; Huber, Lars C <javascript:contributorCitation(
’Huber, Lars C’ );>; Brock, Matthias <javascript:contributorCitation( ’Brock, Matthias’ );>
DOI: https://doi.org/10.1007/s00395-017-0620-7
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-136713
Journal Article
Accepted Version
Originally published at:
Schuoler, Claudio; Haider, Thomas J; Leuenberger, Caroline; Vogel, Johannes; Ostergaard, Louise;
Kwapiszewska, Grazyna; Kohler, Malcolm; Gassmann, Max; Huber, Lars C; Brock, Matthias (2017).
Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells in hypoxia-induced
pulmonary hypertension. Basic Research in Cardiology, 112(3):30.
DOI: https://doi.org/10.1007/s00395-017-0620-7
 1 
Aquaporin 1 Controls the Functional Phenotype of Pulmonary Smooth Muscle Cells in Hypoxia-
Induced Pulmonary Hypertension  
 
 
Claudio Schuoler1,2,3,#, Thomas J. Haider1,2,#, Caroline Leuenberger2,3, Johannes Vogel1, Louise 
Ostergaard1,2, Grazyna Kwapiszewska4, Malcolm Kohler2,3, Max Gassmann1,2, Lars C. Huber3,*, 
Matthias Brock3,* 
 
 
1 Institute of Veterinary Physiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland 
2 Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Zurich, Switzerland 
3 Division of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland 
4 Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria 
# these authors share first authorship 
* these authors share senior authorship 
 
 
Corresponding author: 
Matthias Brock 
Division of Pulmonology 
University Hospital Zurich 
Wagistrasse 14 
8952 Schlieren 
Switzerland 
E-mail: matthias.brock@uzh.ch 
Phone: 0041 44 556 31 60 
 
 
 
 
 
 
 2 
Abstract 
 
Aims: Vascular remodelling in hypoxia-induced pulmonary hypertension (PH) is driven by excessive 
proliferation and migration of endothelial and smooth muscle cells. The expression of aquaporin 1 
(AQP1), an integral membrane water channel protein involved in the control of these processes, is 
tightly regulated by oxygen levels. The role of AQP1 in the pathogenesis of PH, however, has not 
been directly addressed so far. This study was designed to characterize expression and function of 
AQP1 in pulmonary vascular cells from human arteries and in the mouse model of hypoxia-induced 
PH.  
 
Methods and Results: Exposure of human pulmonary vascular cells to hypoxia significantly induced 
the expression of AQP1. Similarly, levels of AQP1 were found to be upregulated in lungs of mice with 
hypoxia-induced PH. The functional role of AQP1 was further tested in human pulmonary artery 
smooth muscle cells demonstrating that depletion of AQP1 reduced proliferation, the migratory 
potential, and, conversely, increased apoptosis of these cells. This effect was associated with higher 
expression of the tumour suppressor gene p53. Using the mouse model of hypoxia-induced PH, 
application of GapmeR inhibitors targeting AQP1 abated the hypoxia-induced upregulation of AQP1 
and, of note, reversed PH by decreasing both right ventricular pressure and hypertrophy back to the 
levels of control mice.  
 
Conclusions: Our data suggest an important functional role of AQP1 in the pathobiology of hypoxia-
induced PH. These results offer novel insights in our pathogenetic understanding of the disease and 
propose AQP1 as potential therapeutic in vivo target.  
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Introduction 
 
Pulmonary hypertension (PH) is the pathophysiological consequence of several diseases and is, in 
many cases, triggered or aggravated by hypoxia [26, 28, 30]. The pulmonary vasculature of PH 
patients is characterized by vasoconstriction, microthrombotic events and excessive remodelling of the 
small pulmonary arteries [9, 24]. Whereas acute hypoxia increases pulmonary pressure by calcium-
mediated vasoconstriction of pulmonary vascular smooth muscle cells on the short term, conditions of 
chronic hypoxia, including many parenchymal lung disease, trigger mechanisms of remodelling that 
result in the development of irreversible pulmonary hypertension [37]. Vascular remodelling is due to 
migration and proliferation of cells within all layers of the vessel wall, most prominently however of 
pulmonary artery smooth muscle and endothelial cells [20]. Uncontrolled proliferation and resistance 
to apoptosis of these cells have also been described as neoplastic-like processes [29]. To date, vascular 
remodelling is not satisfyingly addressed by treatment [7].  
The mammalian aquaporins (AQPs) are a class of water channels that regulate the rapid water 
movement across the plasma membrane in response to an osmotic gradient [18]. The AQP family 
consists of 13 different subsets (AQP0-12) so far which are expressed in multiple organs including the 
lungs. AQPs are involved in various physiological processes such as trans-epithelial fluid transport, 
cell migration, cell proliferation, and angiogenesis [35]. These processes are, probably by the action of 
AQPs, of major importance for the physiological adaption to hypoxia as well as in the 
pathophysiology of cancer[34] and hypoxia-related diseases [27].  
A steadily growing number of studies emphasize that AQPs seem to be strongly involved in stress-
induced tissue transformation processes. Recently, it was suggested that hypoxia modulates AQP1 
expression in different organs, e.g. mouse lungs [1]. Moreover, in rat pulmonary artery smooth muscle 
cells, hypoxia selectively increased AQP1 protein levels and, in turn, migration of these cells [14]. 
These data suggest a possible link between the excessive vascular remodelling observed in patients 
with PH and both expression and function of AQP1.  
However, the role of AQP1 in the pathobiology of vascular remodelling in PH has not been directly 
addressed so far. The present study was designed to investigate the expression and function of AQP1 
in human vascular cells derived from pulmonary arteries and in the mouse model of hypoxia-induced 
PH. In detail, the functional consequence of altered AQP1 expression in human vascular cells was 
assessed with an emphasis on migration, proliferation and resistance to apoptosis. The physiological 
consequences of AQP1 depletion on haemodynamcis were further addressed in vivo by employing the 
hypoxia-induced mouse model of PH. 
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Methods 
 
Animal Experiments 
Male mice (C57BL/6, aged 12 weeks) were obtained from Charles River (Sulzfeld, Germany) and 
used for the hypoxia-induced PH mouse model as previously described in our publications [3, 4]. 
Briefly, the animals were randomized into a normoxic control group (n=8, room air, 21% O2) and a 
hypoxic group (n=8, 10% O2). Normobaric hypoxic condition was provided in a sealed glove-chamber 
connected to a gas mixer (Coy Laboratory Products, Grass Lake, MI, USA). Mice were assessed daily 
for activity and wellbeing. All animals had access to standard diet and tap water ad libitum. At day 35, 
after 5 weeks of hypoxic exposure, mice were anaesthetized (induction: 5% isoflurane, maintenance: 
1.5-2% isoflurane and 100% O2) and systemic arterial pressure (SAP) was measured in the isolated 
femoral artery. Next, right ventricular pressure (RVP) was evaluated as an endpoint measurement of 
PH, performed by right heart catheterization as previously described [10]. Mice were subsequently 
euthanized by cervical dislocation and lungs were collected for further analysis.  
For treatment experiments, an additional mouse experiment was employed. Mice were divided into 
treatment and control groups (four groups of n=8 each). After three weeks of hypoxic exposure (10% 
O2), the hypoxic mice were randomly assigned to three different groups to be further kept untreated or 
treated every four days by intraperitoneal (i.p.) injections with antisense oligonucleotides (GapmeRs) 
directed against AQP1 or GapmeR scrambled negative control (10mg/kg solved in sterile 0.9% NaCl). 
GapmeRs are short oligonucleotides modified with locked nucleic acids (LNA) in the flanking regions 
and DNA in a central gap (hence the name GapmeR). Application of GapmeR AQP1 results in RNase 
H-dependent degradation of complementary AQP1 RNA. 
One mouse (hypoxic GapmeR negative control) died during the course of the experiment. Two weeks 
later, mice were analysed for RVP. The RVP of two hypoxic GapmeR AQP1 mice could not be 
measured since these mice died during right heart catheterization. Afterwards, animals were 
euthanized and lungs were harvested. To assess right ventricular hypertrophy, the ratio between right 
ventricular to left ventricular diameter including interventricular septum (RV/(LV+S)) was calculated 
based on the average of 3 linear diameter measurements across each heart section. All animal 
experiments were approved by the Cantonal Veterinary Office Zurich (approval numbers 151/2012 
and 212/2014) and performed according to the guidelines from Directive 2010/63/EU of the European 
Parliament. 
 
Cell Culture 
Human pulmonary artery smooth muscle (HPASMC) (ScienCell, Carlsbad, CA, USA; donor #1 and 
#2) and human pulmonary artery endothelial cells (HPAEC) (ScienCell, Carlsbad, CA, USA; donor 
#1, and PromoCell, Heidelberg, Germany; donor #2) derived from two healthy donors were expanded 
in cultures according to the manufacturer’s instructions. Cells were incubated in a humidified 
atmosphere at 37°C and 5% CO2. In all experiments, one batch of cells with passage number between 
two and eight was used. Cells were seeded and allowed to settle for at least 12h before being 
transfected or exposed to hypoxia. Hypoxic experiments (1% O2) were carried out over different time 
points (e.g. functional assays for 48h) in an O2 adjustable incubator (Binder, Tutlingen, Germany) 
maintained at 37°C with 5% CO2. 
 
Transient Transfection of Primary Cultured Cells 
For manipulation of endogenous levels of AQP1, HPASMC were transfected with GapmeR targeting 
AQP1 or GapmeR negative control (25nmol/L) using Lipofectamine 2000 transfection reagent (Life 
Technologies, Zug, Switzerland) according to the manufacturer’s protocol. Cell culture grade GapmeR 
inhibitors were obtained from Exiqon (Vedbaek, Denmark) and their sequences are listed in 
Supplementary Table 1. Following an incubation period of 24 or 48h, cells were either harvested for 
gene expression analysis or prepared for functional assays. 
 
Plasmid Construction and Overexpression 
Conventional PCR was used to amplify the coding sequence of AQP1 (809bp) out of cDNA from 
HPASMC. The obtained PCR product was digested with HindIII and XhoI and subsequently cloned 
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into pcDNA 3.1(+) vector (Invitrogen, Basel, Switzerland). Successful insertion of AQP1 was 
confirmed by Sanger sequencing (Microsynth, Balgach, Switzerland). Primers used for cloning are 
provided in Supplementary Table 2. To overexpress AQP1, HPASMC were transfected either with 
0.25µg pcDNA_AQP1 or its corresponding empty vector, which served as a negative control, using 
electroporation technique (Amaxa Nucleofactor kit, Lonza, Basel, Switzerland). Subsequently, after 
48h, cells were harvested and gene overexpression was analysed by Western blotting or cells were 
prepared for migration and proliferation assays. 
 
Quantitative Real-Time PCR (qPCR) Analysis 
Total RNA of cultured cells or murine lung tissue samples were purified using the Quick-RNA 
MiniPrep kit (Zymo Research, Freiburg im Breisgau, Germany) or the miRNeasy Mini kit (Qiagen, 
Hombrechtikon, Switzerland), respectively. Quality of isolated RNA was assessed by 
spectrophotometric analysis (Nanodrop, Wilmington, DE, USA). Isolated RNA was reverse-
transcribed using random hexamers and GoScript reverse transcriptase (both from Promega, 
Dübendorf, Switzerland). Quantification of specific gene transcripts was performed by SYBR Green 
qPCR (Applied Biosystem StepOnePlus system, Life Technologies). To avoid amplification of 
genomic DNA, primers were designed to span an exon-exon junction. Sequences of primers used for 
gene expression analysis are listed in Supplementary Table 2. Specific amplification was verified 
performing melt curve analysis. Obtained expression levels of genes of interest were normalized to the 
expression of β-actin. Differential gene expression was calculated using the threshold cycle (Ct) 
method [25]. 
 
Western Blotting 
For protein extraction, harvested cells and murine lung tissue samples were lysed or homogenized 
using sample loading buffer (62.5mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulphate (SDS), 10% 
glycerol, 5mM β-mercaptoehtanol, bromphenolblue). Whole-cell lysates (30µg of protein) were 
separated by 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
proteins were transferred by electroblotting to a nitrocellulose membrane (Whatman, GE Healthcare 
Life Sciences, Little Chalfont, UK). Membranes were blocked with 5% dry milk in Tris-buffered 
saline containing 0.1% Tween 20 (TBS-T) and incubated over night at 4°C with the following primary 
antibodies: anti-AQP1 (rabbit monoclonal, #ab168387, Abcam, Cambridge, UK), anti-hypoxia-
inducible factor 1 alpha (HIF-1α) (rabbit polyclonal, #NB100-479, Novus Biologicals, Littleton, CO, 
USA), anti-p53 (mouse monoclonal, #sc-126, Santa Cruz Biotechnology, Dallas, TX, USA), and anti-
β-actin (mouse monoclonal, #A2228, Sigma-Aldrich, Buchs SG, Switzerland), respectively. β-actin 
was used as a housekeeping protein for normalization. Bands were detected using species-specific 
secondary antibodies conjugated to horseradish peroxidase (Dako Agilent Technologies, Glostrup, 
Denmark). Calculation of the expression of proteins was performed using Adobe Photoshop CS5.1 
software (Adobe Systems Incorporated, San Jose, CA, USA) via pixel quantification of the electronic 
image. 
 
Migration Assay 
Migration of HPASMC was addressed according to a modified in vitro wound-healing assay. Briefly, 
30’000 cells were seeded on each side of an Ibidi culture insert µ-dish (Ibidi, Munich, Germany) for 
live cell analysis and transfected with GapmeR targeting AQP1 or scrambled negative control as 
described above. In addition, HPASMC were transfected with AQP1 overexpressing vector 
(pcDNA_AQP1) as stated above. Cells were allowed to grow to confluence for 24h and afterwards, 
inserts were removed with sterile tweezers to create a cell-free gap of approximately 500µm width. 
The closure of the wound by migrating cells was quantitatively assessed at various time points after 
being photographed at 4x magnification under an inverted microscope (Olympus CKX41) as 
previously described [21]. The area of the initial wound was compared to the area of the healing 
wound at three different time points (3, 5, and 7h). 
 
Proliferation and Apoptosis Assay 
To assess the proliferation rate, HPASMC were seeded in a 96-well plate at a density of 5000 cells per 
well and transfected with GapmeR targeting AQP1 or scrambled negative control as described above. 
For AQP1 overexpression, 10’000 cells were used and transfected either with pcDNA_AQP1 or its 
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corresponding empty vector as mentioned above. After 24h, 5-bromo-2-deoxyuridine (BrdU) was 
added to each well and cells were incubated for an additional 24h. Incorporation of BrdU was detected 
using the colorimetric BrdU assay from Roche (Roche Diagnostics, Mannheim, Germany). To assess 
apoptosis, HPASMC were seeded in a 96-well plate at a density of 10’000 cells per well and 
transfected with GapmeR targeting AQP1 or scrambled negative control. After 48h, apoptosis was 
evaluated in unstimulated cells (spontaneous apoptosis) by measuring the activity of caspase 3 and 7 
(Caspase-Glo 3/7 assay, Promega, Dübendorf, Switzerland) according to the manufacturer’s protocol. 
 
Statistics 
All data are presented as mean ± standard deviation (SD). Parametric or non-parametric distribution of 
data was determined using the Kolmogorov-Smirnov test. Data comparison was performed using 
independent Student’s t-test as well as Pearson’s correlation for parametric samples. For comparing 
more than two sample groups, the one-way analysis of variance (ANOVA) with Tukey post hoc test 
for parametric samples and the Kruskal-Wallis test with Dunns post hoc test for non-parametric 
samples was used. Paired Student’s t-test or repeated measures ANOVA was used with Tukey post 
hoc test to analyse functional assays and AQP1 gene expression levels (paired observations of the 
same subject). In all statistical analyses, two-sided tests were applied. Values of p<0.05 were 
considered to be statistically significant (*p<0.05, **p<0.01, ***p<0.001). The n number indicates 
independent experiments. All statistical calculations were performed using the software package 
GraphPad Prism Version 5.0a (GraphPad Software, San Diego, CA, USA). 
 
 7 
Results 
 
AQP1 expression is increased in the mouse model of hypoxia-induced PH. 
The regulation of AQP1 by hypoxia was characterized in lung samples of the mouse model of 
hypoxia-induced PH. As presented in Figure 1a, mice exposed to chronic hypoxia showed a 
significant elevation in RVP compared to normoxic control mice (in mmHg: hypoxic mice 45.45±3.63 
vs. normoxic mice 30.83±2.60, p<0.001) indicating a successful in vivo application of the hypoxia-
induced PH model. In lung tissue obtained from these mice, mRNA levels of AQP1 were significantly 
upregulated after hypoxia compared to normoxic control animals (by 1.31±0.14 fold change, p<0.01; 
Fig. 1b). These data were confirmed on protein level by Western blotting. AQP1 protein levels were 
significantly increased after exposure to chronic hypoxia (by 1.92±0.70 fold change, p<0.01; Fig. 1c). 
Since the levels of AQP1 were significantly upregulated under hypoxic conditions, a correlation 
analysis was performed showing a significant positive correlation of AQP1 protein levels with the 
RVP of experimental animals (r=0.636, p<0.01; Fig. 1d). 
 
AQP1 is expressed in human pulmonary vascular cells. 
In a next step, the basal expression levels of AQP1 in HPASMC and HPAEC, the two main cell types 
being involved in the process of vascular remodelling, were investigated. Both cell types express 
AQP1 on mRNA as well as protein levels. An increased mRNA expression of AQP1 in HPAEC was 
observed compared to HPASMC (e.g. ΔCt of 8.74±2.01 in HPAEC donor #1 vs. ΔCt of 15.09±0.56 in 
HPASMC donor #2, p<0.05; Fig. 2a). On protein level, there was no significant difference in the 
expression levels of AQP1 between the two donors of pulmonary vascular cell types (Fig. 2b). 
 
Exposure to hypoxia drives the expression of AQP1 in human pulmonary vascular cells. 
To further investigate the role of AQP1 in hypoxia-induced PH, pulmonary cells were exposed to 
hypoxia over different time points (1% O2 for 2-72h). As indicated in Figure 3a, HPAEC showed the 
highest peak in AQP1 mRNA expression after 8h of hypoxic exposure (by 1.63±1.12 fold change, not 
significant; donor #1), whereas long-term hypoxia (24-72h) decreased mRNA levels with a significant 
reduction after 72h in donor #2 (reduction to 0.07±0.04, p<0.05). mRNA levels of AQP1 in HPASMC 
(donor #1) were significantly upregulated after 8h (by 2.18±0.80 fold change, p<0.05), 24h (by 
2.87±0.89 fold change, p<0.001) and 48h (by 2.10±0.34 fold change, p<0.05) of hypoxic exposure. In 
donor #2, however, hypoxia did not change AQP1 mRNA levels (Fig. 3b). Protein expression of 
AQP1 in HPAEC was only found significant after 72h of hypoxia in donor #2 (by 1.88±0.49 fold 
change, p<0.01; Fig. 3c). In contrast, long-term hypoxia increased AQP1 protein levels in HPASMC, 
with a significant elevation after 48h (by 1.80±0.36 fold change, p<0.05; donor #1) and e.g. 72h (by 
2.18±0.15 fold change, p<0.001; donor #2) of hypoxic exposure (Fig. 3d). Successful application of 
the hypoxic condition is indicated by representative Western blots of HIF-1α stabilization (Fig. 3c, d) 
as well as marked increase in mRNA levels of the HIF-1α inducible gene VEGFα (positive control, 
data not shown). 
 
Silencing of AQP1 affects the phenotype of human pulmonary artery smooth muscle cells. 
Since there was no difference in the amount of AQP1 protein expression in HPASMC and HPAEC 
(Fig. 2b) and the fact that HPASMC responded best to the hypoxic condition (Fig. 3), we focused on 
the latter cell type to continue with and to perform the following experiments and functional assays.
  
To evaluate the physiological role of AQP1 in the process of migration, proliferation and apoptosis in 
HPASMC, the endogenous expression of AQP1 was silenced by transfection with GapmeRs. As 
measured by qPCR, transfection of HPASMC with GapmeR targeting AQP1 significantly reduced the 
expression of AQP1 compared to non-transfected and negative control transfected cells in donor #1 
(by 0.42±0.19 fold change, p<0.01; Fig. 4a). Additionally, these data were confirmed on protein level 
by Western blots demonstrating a significant decrease of AQP1 protein levels in donor #1 (by 
0.66±0.13 fold change, p<0.01; Fig. 4b). 
In terms of migration, as shown in Figure 4c, silencing of AQP1 in HPASMC significantly lowered 
the rate of healing in wound healing assays (e.g. after 7h of migration: GapmeR negative control 
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39.38%±5.00 vs. GapmeR AQP1 28.88%±7.86, p<0.001; donor #1). Representative pictures of 
migrated HPASMC are provided in Supplementary Figure 1. Likewise, as assessed by BrdU 
incorporation assay, transfection with GapmeR AQP1 resulted in a significantly reduced proliferation 
rate of HPASMC (donor #1) compared to non-transfected and GapmeR negative control transfected 
cells (in absorbance at 450nm: GapmeR negative control 1.76±0.17 vs. GapmeR AQP1 1.45±0.24, 
p<0.01; Fig. 4d). Conversely, HPASMC depleted of AQP1 showed significantly higher caspase 3/7 
activity compared to both non-transfected and negative control transfected cells (in relative 
luminescence units: GapmeR negative control 4138±1106 vs. GapmeR AQP1 5558±1630, p<0.01; 
Fig. 4e) indicating a higher degree of spontaneous apoptosis when AQP1 is silenced. All results were 
confirmed using a second donor of HPASMC. 
 
Silencing of AQP1 affects the phenotype of hypoxic human pulmonary artery smooth muscle 
cells. 
To investigate the function of AQP1 under hypoxic conditions, HPASMC were transfected with 
GapmeR AQP1, exposed to hypoxia and, 48h later, their functional profile was assessed. As indicated 
in Figure 5a, inhibiting AQP1 resulted in significantly less hypoxic migration of HPASMC compared 
to non-transfected as well as negative control transfected cells (e.g. donor #1: rate of healing in % after 
7h: Hx GapmeR negative control 31.88%±4.06 vs. Hx GapmeR AQP1 10.45%±4.36, p<0.001). 
Representative pictures of migrated HPASMC are provided in Supplementary Figure 2. Additionally, 
hypoxic HPASMC depleted of AQP1 showed significantly lower proliferation compared to control 
transfected cells (donor #1 in absorbance at 450nm: Hx GapmeR negative control 0.57±0.21 vs. Hx 
GapmeR AQP1 0.17±0.04, p<0.01; Fig. 5b). Of note, GapmeR neg. control transfected cells had 
significantly less proliferation rates compared to hypoxic non-transfected control cells. Moreover, in 
terms of apoptosis, HPASMC transfected with GapmeR AQP1 and exposed to hypoxia showed 
significantly higher caspase 3/7 activity in comparison to both control setups (donor #1 in relative 
luminescence units: e.g. Hx GapmeR negative control 1415±181 vs. Hx GapmeR AQP1 8538±767, 
p<0.001; Fig. 5c). Using a second donor of HPASMC, all results were confirmed. In summary, our 
experiments highlight the importance of AQP1 in the regulation of apoptosis, migration, and 
proliferation of HPASMC in normoxic as well as hypoxic conditions. 
 
AQP1 controls the expression of p53 in human pulmonary artery smooth muscle cells. 
To elucidate the molecular mechanism of AQP1 depletion in HPASMC, tumour suppressor and cell 
cycle inhibitor genes that have been previously implicated in the pathogenesis of PH were 
characterized in HPASMC transfected with GapmeR targeting AQP1. In detail, the mRNA levels of 
p53, BCL2, CDKN1A, and CDKN2A were measured by qPCR demonstrating a significant 
upregulation of p53 after transfection with GapmeR targeting AQP1 (by 1.43±0.15 fold change for 
donor #1 and by 3.18±0.54 fold change for donor #2, p<0.001; Fig. 6a), whereas no significant 
changes could be observed when the expression of the other genes was assessed (data not shown). 
Along that line, protein levels of p53 were significantly increased in both donor #1 by 2.97±0.77 fold 
change (p<0.001) and donor #2 by 5.18±3.18 fold change (p<0.05; Fig. 6b) when AQP1 was depleted 
in HPASMC compared to negative control transfected cells. Of interest, the expression of p53 was 
decreased in both HPASMC donors exposed to long-term hypoxia (e.g. 72h of hypoxia: 0.71±0.11 
fold change for donor #1 and 0.55±0.20 fold change for donor #2, p<0.01; Fig. 6c). Western blots 
confirmed these results on protein level demonstrating a significant decrease of p53 after 72h of 
hypoxia in donor #1 and #2 (0.67±0.11 fold change and 0.52±0.05 fold change, respectively, p<0.05; 
Fig. 6d). These results highlight the regulation of the expression of p53 by AQP1 and hypoxia in 
HPASMC. 
 
Enforced expression of AQP1 enhances migration and proliferation of human pulmonary artery 
smooth muscle cells. 
To further confirm the role of AQP1 in the context of pulmonary vascular remodelling, AQP1 
overexpression studies were performed in HPASMC. As demonstrated by the representative Western 
blot in Figure 7a, protein expression of AQP1 was significantly increased after transfection with 
pcDNA_AQP1 (donor #1 by 13.76±3.72 fold change, p<0.001). Regarding the migratory potential, 
HPASMC overexpressing AQP1 migrated faster than control cells as assessed by wound-healing 
assay (e.g. donor #1: rate of healing in % after 7h: pcDNA_empty 17.88%±5.52 vs. pcDNA_AQP1 
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24.83%±5.36, p<0.001; Fig. 7b). Representative pictures of migrated HPASMC are provided in 
Supplementary Figure 3. Moreover, as assessed by BrdU incorporation assay, HPASMC 
overexpressing AQP1 showed enhanced proliferation rates compared to HPASMC transfected with 
empty control vector (donor #1 in absorbance at 450nm: pcDNA_empty 0.57±0.17 vs. pcDNA_AQP1 
0.77±0.18, p<0.01; Fig. 7c). All results were confirmed using a second donor of HPASMC. 
 
Silencing of AQP1 reduces right ventricular pressure in the mouse model of hypoxia-induced 
PH. 
The physiological consequences of AQP1 depletion via intervention experiments were further 
addressed in vivo by employing the hypoxia-induced mouse model of PH. The in vivo experiments 
were performed as described in the section ‘Methods’ (Fig. 8a).  
As shown in Figure 8b, hypoxic control mice showed a significant increase in RVP compared to 
normoxic animals (in mmHg: 38.40±3.71 vs. 30.33±2.32, p<0.05) confirming the development of PH. 
Repeated i.p. injections of negative control GapmeR had no effect on RVP since RVP stayed 
significantly elevated in comparison with normoxic control. In contrast, treatment with GapmeR 
targeting AQP1 significantly reduced RVP in these mice compared to hypoxic GapmeR negative 
control mice (hypoxic GapmeR AQP1 mice 29.77±8.08 vs. hypoxic GapmeR negative control mice 
41.00±3.40, p<0.01; Fig. 8b). Importantly, after treatment with GapmeR AQP1, RVP of these mice 
dropped to the same level as in normoxic control animals (Fig. 8b). Of note, systemic arterial pressure 
and haematocrit were not affected by GapmeR application indicating selective effects of GapmeR 
within the pulmonary circulation (Fig. 8c, d). Planimetric analysis of the ratio between right 
ventricular to left ventricular diameter including interventricular septum (RV/(LV+S)) showed a 
significant increase of the right ventricular volume following exposure to hypoxia (0.295±0.079) as 
compared to normoxic controls (0.183±0.039, p<0.01). Upon treatment with GapmeR against AQP1, 
the ratio was decreased (0.204±0.029, p<0.05; Fig. 8e). 
In lung tissue collected from these mice, AQP1 mRNA levels were significantly elevated after 
hypoxic exposure compared to normoxic control mice (by 1.36±0.14 fold change, p<0.01; Fig. 8f) 
being in line with Figure 1b. Moreover, repeated i.p. injections of GapmeR targeting AQP1 
significantly downregulated mRNA levels of AQP1 in lung tissue compared to hypoxic GapmeR 
negative control animals (hypoxic GapmeR negative control mice 1.24±0.28 fold change vs. hypoxic 
GapmeR AQP1 mice 0.97±0.14 fold change, p<0.05; Fig. 8f). Treatment with GapmeR AQP1 had no 
effect on mRNA levels of other AQPs expressed in the lung (AQP2-5), confirming specificity of the 
GapmeR design. Hypoxia, however, was able to significantly upregulate the expression of AQP4 and 
AQP5 (Supplementary Figure 4). 
Affirming the results of the mRNA expression analysis, protein expression of AQP1 was found to be 
significantly upregulated in both hypoxic and hypoxic GapmeR negative control mice compared to 
normoxic control animals (hypoxic mice: by 2.77±1.23 fold change, hypoxic GapmeR negative 
control mice: by 2.90±0.87 fold change, p<0.01 and p<0.001, respectively; Fig. 8g). Administration of 
GapmeR AQP1 tended to reduce the protein expression of AQP1 to levels between normoxic and 
hypoxic animals (hypoxic GapmeR AQP1 mice 2.02±0.67 fold change vs. normoxic mice 1.00±0.36 
fold change, not significant; Fig. 8g). 
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Discussion 
 
AQP1 is known to be induced by hypoxia which itself might be both a causative factor for and a 
consequence of elevated pulmonary pressure. Of interest, however, the physiological consequence of 
the manipulation of AQP1 expression has not been described in the context of hypoxia-induced PH so 
far. In this study, we confirmed previous findings showing that hypoxic conditions increase the 
expression of AQP1 both in vitro and in vivo [14]. In addition, we demonstrated that manipulation of 
AQP1 affects the expression of the tumour suppressor gene p53 and influences the functional profile 
of pulmonary vascular cells on a migratory, proliferative and apoptotic level. By employing the 
hypoxia-induced PH mouse model, we found that silencing of AQP1 by a novel chimeric antisense 
oligonucleotide technology (GapmeRs) reversed established PH. Taken together, these findings 
represent the first direct link between AQP1 and PH and provide a novel interesting target to address 
pulmonary hypertension.  
It was previously reported that AQP1 is induced by hypoxia in pulmonary artery smooth muscle cells. 
In detail, rat pulmonary artery smooth muscle cells exposed to hypoxia selectively increased AQP1 
protein levels and, in turn, migration. Silencing of AQP1 via siRNA prevented the hypoxia-induced 
migration in these cells [13, 14]. Our initial experiments confirmed these findings by showing that the 
levels of AQP1 are increased by hypoxia in pulmonary artery smooth muscle cells. Of note, the 
observed induction of AQP1 could not be directly linked to the stabilization of HIF-1α suggesting the 
involvement of other mechanisms [1], for example the additional influx of calcium or interaction with 
microRNAs as suggested previously [14, 22]. The multi-factorial and complex induction of AQP1 by 
hypoxia is further emphasized by variable mRNA levels between the two donors. While the exact 
mechanisms behind these findings are elusive, high protein levels and functional data were 
consistently retrieved in long-term exposed HPASMC. Moreover, in lung tissue samples of animals 
exposed to hypoxia for five weeks, we found a significant increase in the expression of AQP1 
compared to normoxic controls. Levels of AQP1 could be further correlated with pulmonary 
hemodynamics indicating that mice with higher AQP1 expression levels have increased right 
ventricular pressures and vice versa. Functional experiments and a subsequent treatment trial 
emphasized that this correlation might reflect causality and not only association.   
Pulmonary artery smooth muscle cells showed an increased migratory response and dysregulation of 
the cell growth with development of a pro-proliferative and anti-apoptotic phenotype. Remodelling of 
small pulmonary arteries is the major factor in the pathobiology of PH and is, to date, not adequately 
addressed by modern PH-target therapies. Along that line, a recent publication demonstrated that 
genetic deletion of endothelial guanylyl cyclase-A receptor in mice caused pulmonary vascular 
remodelling, probably due to increased vascular cell proliferation, and PH already under normoxic 
conditions since the atrial natriuretic peptide (ANP) cannot exert its protective effects. This 
experimental study underpins the importance for novel strategies to target or even reverse pulmonary 
vascular remodelling and PH [38]. Vascular remodelling in the pulmonary circulation is characterized 
by migration of endothelial cells reflecting angiogenesis [36], formation of a “neo-intima” [20] and, 
most important, uncontrolled proliferation of smooth muscle cells [5]. These changes that result in 
progressive hyperplasia of the medial vessel layer and luminal obliteration have been described as 
neoplastic-like processes [29]. Since AQPs have been associated with malignant transformation and 
the development of cancer, our results might provide a novel mechanism explaining similar 
transformation in vessels of patients with PH. One of the best characterized tumour suppressor genes 
is p53 [32] and, in the context of PH, Jacquin et al. showed that p53 is found downregulated in the 
monocrotaline model of PH. Moreover, inactivation of p53 alone was sufficient to induce the 
development of experimental PH [11, 16]. Another study demonstrated that exogenous NO has an 
inhibitory effect on smooth muscle cell proliferation via induction of p53 and p21 [17]. In our 
experiments, silencing of AQP1 via GapmeRs resulted in higher mRNA and protein expression of 
p53. The interaction between p53 and AQP1 was further highlighted in hypoxic HPASMC showing 
decreased p53 levels with a concomitant increase of AQP1 expression (Figure 9). Additionally, 
enhanced p53 expression levels were found after silencing of AQP3 with shRNA in a non-small cell 
lung cancer (NSCLC) model, which was accompanied with suppressed tumour proliferation [39]. 
AQP3 knockdown reduced cellular glycerol content (AQP3 is a aquaglyceroporin) and mitochondrial 
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ATP formation, which, together with a reduction in PCNA levels, might contribute to the inhibitive 
effect on tumour proliferation. Of note, the importance of AQP1 for the vascular smooth muscle 
phenotype was highlighted in a study by Al Ghouleh et al. demonstrating that reactive oxygen species 
are channelled via AQP1 resulting in hypertrophy, however without affecting proliferation [2]. 
Furthermore, a study investigated the role of the C-terminal tail of AQP1 on migration and 
proliferation because the exact mechanism by which AQP1 facilitates these two processes remains 
unclear [13]. In this setting, the C-terminal was required since its deletion in AQP1 overexpressing rat 
smooth muscle cells abolished the effect on both migration and proliferation. They concluded that the 
possible AQP1-mediated mechanisms include association of factors or proteins with the C-terminal. 
The exact mechanism how AQP1 executes its function in this context, however, remains elusive and it 
will be difficult in general to unravel the underlying molecular mechanisms that act at the interface of 
hypoxia, AQP1, and PH.  
Another link between AQP1 and proliferation was provided by data on adult carotid body cells, which 
were observed to proliferate less under hypoxic conditions when analysed in AQP1 knockout mice. 
Microarray data further revealed alterations in several proliferation-regulating genes suggesting that 
AQP1 modifies the expression of key cell cycle proteins [6].  
In a next step, we tried to translate these in vitro findings by antagonizing AQP1 in an experimental 
model for PH. Animal models used to investigate PH have major limitations and only partially mimic 
human disease [8]. However, the hypoxia-induced mouse model is one of the best-established models 
for PH and, in the context of AQP1 that is strongly driven by hypoxic conditions, represents a suitable 
in vivo model. Silencing of AQP1 was achieved by administration of GapmeRs directed against 
AQP1. GapmeRs are single-stranded antisense oligonucleotides that catalyse the RNase H mediated 
degradation of complementary RNA targets and are active both in vitro and in vivo. To ensure 
enhanced stability and high target affinity, GapmeRs are composed of LNA-modified oligonucleotides 
flanking a central gap of DNA [33]. The usage of GapmeRs to target transcripts of genes of interest in 
vivo has been shown previously [31].  
In this study, repeated intraperitoneal application of GapmeRs resulted in antagonizing of AQP1 and 
reversed the hypoxia-induced elevation of the pulmonary pressure. This is, to the best of our 
knowledge, the first report on the successful targeting of AQP1 in vivo through GapmeRs. In turn, as a 
consequence of reduced AQP1 expression in lung tissue, right ventricular pressure in animals exposed 
to hypoxia was reduced to levels of normoxic control animals. Performing additional experiments 
measuring mRNA levels of AQP2-5 in whole tissue from lungs in our GapmeR mouse setting of 
hypoxia-induced PH confirmed specificity of GapmeR for AQP1, where hypoxia was able to 
significantly upregulate the expression of AQP4 and AQP5 (Supplementary Figure 4). Furthermore, 
these results indicate that there was no compensational feedback regulation of other AQP subsets due 
to GapmeR treatment. A limitation of this study is the near absence of right ventricular hypertrophy in 
the Hx GapmeR neg. ctl group. This might be explained by a combination of methodical limitations of 
applied morphometric analysis and the relatively high biological variation, which was observed in our 
hypoxia-induced PH mouse model. Although this mouse model is frequently applied, it is supposed to 
be a mild one in terms of RVP increase, RVH, and pulmonary vascular remodelling [15]. However, 
RVP was significantly elevated in this group after hypoxic exposure. Newly established animal 
models for hypoxia-induced PH, e.g. the Sugen/hypoxia [19], were shown to induce a more 
pronounced pathological cardiorespiratory phenotype. Nevertheless, our data indicate that the 
pharmacological use of GapmeRs to target AQP1 reverses hypoxia-induced elevated pulmonary 
pressure and might treat vascular remodelling. The use of these novel antisense oligonucleotides could 
be limited by non-specific binding to proteins and off-target effects such as hepatotoxicity [12]. In our 
experiments, however, no such effects were observed indicating that GapmeR therapy is well tolerated 
and feasible.  
In conclusion, this is the first report of AQPs in the context of PH. The identification of AQP1 
expression and its functional characterization upon exposure to hypoxia unravels novel and important 
insights in the pathogenesis of pulmonary vascular remodelling. The therapeutic application of 
innovative antisense oligonucleotides resulted in successful antagonization of AQP1 and reversed 
experimental PH. However, it remains elusive at the moment whether these results might offer a future 
opportunity to target AQP1 in the lungs in order to prevent vascular remodelling in a selected cohort 
of patients with PH in the context of chronic lung disease. 
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Figure Legends 
 
Fig. 1 AQP1 expression is increased in the mouse model of hypoxia-induced PH. Mice were exposed 
to 10% O2 for 5 weeks or kept under normoxia as controls. (a) Right ventricular pressure (RVP, in 
mmHg) measured by right heart catheterization in normoxic (Nx) and hypoxic (Hx) mice. Effect of 
hypoxia on mRNA (b) and protein (c) levels of AQP1 from lung homogenates measured by qPCR and 
Western Blot compared to normoxic animals. A representative blot is provided (30µg). (d) Correlation 
analysis of AQP1 protein expression with RVP of the corresponding mouse. n=8 mice per group. 
Statistical analysis by unpaired Student’s t-test (a-c) and Pearson’s correlation (d) (**p<0.01, 
***p<0.001) 
 
Fig. 2 AQP1 is expressed in human pulmonary vascular cells. Human pulmonary artery endothelial 
(HPAEC) and smooth muscle cells (HPASMC) express AQP1 on mRNA (a) as well as protein (b) 
level. A representative Western blot is shown (30µg). n=4-5 per group. Statistical analysis by Kruskal-
Wallis test with Dunns post hoc test (a) and one-way ANOVA with Tukey post hoc test (b) (*p<0.05, 
**p<0.01) 
 
Fig. 3 Exposure to hypoxia drives the expression of AQP1 in human pulmonary vascular cells. Two 
different donors for both vascular cell types were exposed to hypoxia (1% O2 for 2-72h). (a, b) Effect 
of hypoxia on mRNA levels in HPAEC and HPASMC. (c, d) Effect of hypoxia on protein levels in 
HPAEC and HPASMC. Representative Western blots are provided (30µg). Immunodetection of HIF-
1α was used to confirm successful application of hypoxia. n=5-6 per group. Statistical analysis by 
Kruskal-Wallis test with Dunns post hoc test (a, c) and one-way ANOVA with Tukey post hoc test (b, 
d) (*p<0.05, **p<0.01, ***p<0.001) 
 
Fig. 4 Silencing of AQP1 affects the phenotype of HPASMC. Consequence of GapmeR transfection 
against AQP1 (25nmol/L) on both mRNA (a) and protein (b) levels in two donors of HPASMC 
compared to non-transfected and GapmeR negative control transfected cells. Representative Western 
blots are shown (30µg). Wound-healing (c) and BrdU incorporation (d) assays were performed 
assessing migration (rate of healing in %) and proliferation (absorbance at 450nm) of HPASMC after 
GapmeR AQP1 transfection. (e) Effect of AQP1 depletion in HPASMC on apoptosis as assessed by a 
luminescent assay that measures caspase-3 and -7 activities simultaneously (relative luminescence 
units). n=5-6 per group. Statistical analysis by repeated measures ANOVA with Tukey post hoc test (a 
and b top, c, d and e top) and paired Student’s t-test (a, b, d and e bottom) (*p<0.05, **p<0.01, 
***p<0.001) 
 
Fig. 5 Silencing of AQP1 affects the phenotype of hypoxic HPASMC. Cells were transfected with 
GapmeR AQP1 (25nmol/L), exposed to hypoxia and, 48h later, their functional profile was assessed. 
Migratory (a) (rate of wound healing in %) and proliferative (b) (absorbance at 450nm) responses of 
HPASMC after depletion of AQP1 via GapmeR compared to control cells. (c) Apoptosis of HPASMC 
transfected with GapmeR targeting AQP1 as evaluated by a luminescent assay that measures caspase-
3 and -7 activities simultaneously (relative luminescence units). n=5-6 per group. Statistical analysis 
by repeated measures ANOVA with Tukey post hoc test (a, b, c) (*p<0.05, **p<0.01, ***p<0.001). 
 
Fig. 6 AQP1 controls the expression of p53 in HPASMC. Upon transfection with GapmeR targeting 
AQP1 (25nmol/L), mRNA (a) and protein (b) levels of p53 in two donors of HPASMC were 
evaluated relatively to control cells. Effect of hypoxia (1% O2 for 2-72h) in HPASMC on mRNA (c) 
and protein (d) expression of p53. Representative Western blots are provided (30µg). n=5-6 per group. 
Statistical analysis by repeated measures ANOVA with Tukey post hoc test (a, b top), paired student’s 
t-test (a, b bottom) and one-way ANOVA with Tukey post hoc test (c, d) (*p<0.05, **p<0.01, 
***p<0.001) 
 
Fig. 7 Enforced expression of AQP1 enhances migration and proliferation of HPASMC. Cells were 
transfected with a vector overexpressing AQP1 (pcDNA_AQP1). (a) AQP1 protein levels after 
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transfection with pcDNA_AQP1 (0.25µg) compared to empty control vector transfected cells 
(pcDNA_empty). A representative Western blot is shown (30µg). Migration (b) and proliferation (c) 
in AQP1 overexpressing HPASMC compared to control transfected cells as assessed by wound-
healing (rate of healing in %) and BrdU incorporation (absorbance at 450nm) assays. n=5-6 per group. 
Statistical analysis by paired student’s t-test (a, c) and repeated measures ANOVA with Tukey post 
hoc test (b) (*p<0.05, **p<0.01, ***p<0.001) 
 
Fig. 8 Silencing of AQP1 reduces right ventricular pressure in the mouse model of hypoxia-induced 
PH. (a) Study design of the in vivo experiments. Four groups of eight animals each (n=7 for hypoxia 
GapmeR negative control) were used: three groups were employed in conditions at 10% O2 for 5 
weeks and, after 3 weeks, treated either with GapmeR negative control or GapmeR AQP1 (both 
10mg/kg). Injections were performed intraperitoneally (i.p.) every fourth day. One group served as a 
normoxic control group. Hemodynamic assessment of the mouse model of hypoxia-induced PH shows 
(b) right ventricular pressure (RVP, in mmHg) measured by right heart catheterization (RHC), (c) 
systemic arterial pressure (SAP, in mmHg) and (d) haematocrit (%) in the three hypoxic (Hx) mouse 
groups compared to normoxic (Nx) animals. (e) Planimetric analysis of the ratio between the right to 
left ventricular volume including interventricular septum wall (RV/LV+S) (n=6-8). Effect of hypoxia 
and GapmeR treatment on AQP1 mRNA (f) and protein (g) expression in lung homogenates measured 
by qPCR and Western blot (n=7-8). A representative Western blot is provided (30µg). Statistical 
analysis by one-way ANOVA with Tukey post hoc test (b-g) (*p<0.05, **p<0.01, ***p<0.001) 
 
Fig. 9 Proposed AQP1-mediated mechanism of vascular remodelling in the context of hypoxia-
induced PH. Hypoxia-induced upregulation of AQP1 leads to a reduced expression of the tumour 
suppressor p53, promoting vascular smooth muscle cell proliferation (left side). As described by 
Saadoun et al. [23], AQP1 expression polarises to the leading edge of lamellipodia extension, 
facilitating water influx and cell migration (right side). 
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Figure 2 
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Figure	3		
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Supplementary Table 1: Antisense LNA GapmeR sequences used for silencing of AQP1. + = prefix 
for LNA. Modification: phosphorothioate backbone. 
 
GapmeR Sequence LNA content 
GapmeR negative ctl 5’ – +G+A+C TAA TGC ATT +A+T+C – 3’ 6 
GapmeR AQP1 5’ – +T+G+T CAG AGT GTC +T+A+C – 3’ 6 
 
 
 
Supplementary Table 2: Primer sequences used for cloning of AQP1 and the validation of different 
genes by qPCR. hsa: Homo sapiens. mmu: Mus musculus. 
Gene Primer forward Primer reverse 
β-actin (hsa, mmu) 5’ – TCA AGA TCA TTG CTC CTC CTG AG – 3’ 5’ – TCC TGC TTG CTG ATC CAC ATC – 3’ 
AQP1 (hsa) 5’ – ACC TCC TGG CTA TTG ACT ACA C – 3’ 5’ – GGT TGC TGA AGT TGT GTG TGA TC – 3’ 
AQP1 (mmu) 5’ – ACT TGG CCG CAA TGA CCT GG – 3’ 5’ – CAG AGT GCC AAT GAT CTC AAT GC – 3’ 
p53 (hsa) 5’ – AGC CAC CTG AAG TCC AAA AAG – 3’ 5’ – CCC TTC TGT CTT GAA CAT GAG – 3’ 
AQP1 cloning Primer forward Primer reverse 
Nested PCR 5’ – ATG GCC AGC GAG TTC AAG – 3’ 5’ – CTA TTT GGG CTT CAT CTC C – 3’ 
Reverse PCR 5’ – AAA CTT AAG CTT GCC GCC ATG GCC AGC GAG TTC AAG – 3’ 
5’ – CTA GAC TCG AGC TAT TTG GGC TTC 
ATC TCC – 3’ 
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Supplementary Figure 1: Representative pictures of HPASMC (donors #1 and #2) migrated for 7h in normoxia after 
transfection with GapmeR targeting AQP1 compared to non-transfected or GapmeR negative control transfected cells. 
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Supplementary Figure 2: Representative pictures of HPASMC migrated for 7h in hypoxia (Hx) after transfection with 
GapmeR targeting AQP1 compared to non-transfected or GapmeR negative control transfected cells. 
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Supplementary Figure 3: Representative pictures of HPASMC migrated for 7h after transfection with AQP1 overexpressing 
vector (pcDNA_AQP1) compared to empty control transfected cells (pcDNA_empty). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0h
 m
igr
at
ion
 (T
0) 
7h
 m
igr
at
ion
 (T
3) 
pcDNA_empty pcDNA_AQP1 
